托珠单抗治疗COVID-19:随机对照试验的荟萃分析、试验序贯分析与荟萃回归
该研究纳入10项随机对照试验(其中9项报告主要结局数据),共6493例COVID-19住院患者,3358例(52.2%)分配至托珠单抗组,对照组为标准治疗或安慰剂。主要结局28-30天死亡率:托珠单抗组24.4% vs 对照组29.0%,OR 0.87(95%CI 0.74-1.01),p=0.07,I2=10%,试验序贯分析校正CI 0.66-1.14。荟萃回归提示治疗效应与死亡风险相关,风险越高获益可能越大(logOR vs %risk beta=-0.018,95%CI -0.037至-0.002,p=0.07)。托珠单抗减少机械通气需求,复合次要结局有获益,但未减少ICU入住。结论认为托珠单抗可能带来短期死亡率获益,但需进一步高质量数据。
要点
- 住院COVID-19患者使用托珠单抗,28-30天死亡率24.4% vs 对照组29.0%,OR 0.87(95%CI 0.74-1.01),p=0.07,未达统计学显著。
- 试验序贯分析校正后CI为0.66-1.14,提示当前证据尚不足以确认死亡率获益。
- 荟萃回归提示治疗效应与死亡风险相关,风险越高获益可能越大(logOR vs %risk beta=-0.018,95%CI -0.037至-0.002,p=0.07)。
- 托珠单抗减少机械通气需求,复合次要结局有获益,但未减少ICU入住。
- 作者认为托珠单抗可能带来短期死亡率获益,但需进一步高质量数据。
适用人群与场景
- 住院COVID-19患者,纳入随机对照试验中分配至托珠单抗组的患者;对照组为标准治疗或安慰剂;同时接受其他COVID-19药物干预的试验未被排除。
研究设计与关键结果
- 研究类型:系统评价、荟萃分析、试验序贯分析与荟萃回归,纳入10项随机对照试验,其中9项报告主要结局(死亡率)数据。
- 样本量:共6493例患者,其中3358例(52.2%)分配至托珠单抗组。
- 主要结局(28-30天死亡率):托珠单抗组24.4% vs 对照组29.0%,OR 0.87(95%CI 0.74-1.01),p=0.07,I2=10%,试验序贯分析校正CI 0.66-1.14。
- 荟萃回归:治疗效应与死亡风险相关,风险越高获益可能越大(logOR vs %risk beta=-0.018,95%CI -0.037至-0.002,p=0.07)。
- 次要结局:托珠单抗减少机械通气需求,复合次要结局有获益,但未减少ICU入住。
证据类型、等级与局限
- 证据类型:随机对照试验的系统评价与荟萃分析。
- 局限:作者指出需要进一步高质量数据。
对床旁实践的改变
- 作者认为,对于住院COVID-19患者,托珠单抗的使用可能带来短期死亡率获益,但需进一步高质量数据。
- 作者认为,托珠单抗的获益可能还在于减少机械通气需求。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: Interleukin-6 (IL-6) levels discriminate between patients with mild and severe COVID-19, making IL-6 inhibition an attractive therapeutic strategy. We conducted a systematic review, meta-analysis, trial sequential analysis (TSA), and meta-regression of randomized-controlled trials to ascertain the benefit of IL-6 blockade with tocilizumab for COVID-19.
METHODS: We included randomized-controlled trials (RCTs) allocating patients with COVID-19 to tocilizumab. Our control group included standard care or placebo. Trials co-administering other pharmacological interventions for COVID-19 were not excluded. Primary outcome was 28-30 day mortality. Secondary outcomes included progression-to-severe disease defined as need for mechanical ventilation, intensive-care unit (ICU) admission, or a composite.
RESULTS: We identified 10 RCTs using tocilizumab, 9 of which reported primary outcome data (mortality), recruiting 6493 patients with 3358 (52.2%) allocated to tocilizumab. Tocilizumab may be associated with an improvement in mortality (24.4% vs. 29.0%; OR 0.87 [0.74-1.01]; p = 0.07; I2 = 10%; TSA adjusted CI 0.66-1.14). Meta-regression suggested a relationship between treatment effect and mortality risk, with benefit at higher levels of risk (logOR vs %risk beta = -0.018 [-0.037 to -0.002]; p = 0.07). Tocilizumab did reduce the need for mechanical ventilation and was associated with a benefit in the composite secondary outcome but did not reduce ICU admission.
CONCLUSIONS: For hospitalized COVID-19 patients, there is some evidence that tocilizumab use may be associated with a short-term mortality benefit, but further high-quality data are required. Its benefits may also lie in reducing the need for mechanical ventilation.
参考来源
- Snow TAC, Saleem N, Ambler G, et al. Tocilizumab in COVID-19: a meta-analysis, trial sequential analysis, and meta-regression of randomized-controlled trials. Intensive Care Med. 2021. PMID: 34019122. doi:10.1007/s00134-021-06416-z
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。